• Allogeneic stem cell marrow transplantation results in long-term disease-free survival in fewer than 40% of patients with accelerated phase disease and is unavailable to most patients owing to lack of a suitable donor or advanced age. (bloodjournal.org)
  • In accelerated phase CML, the cancer cells often acquire new genetic mutations that may make treatments less effective. (lls.org)
  • Xencor acknowledged today that the FDA has placed the company's Phase I trial of its CD123 x CD3 bispecific antibody XmAb®14045 on a partial clinical hold following the deaths of two patients linked to the blood cancer candidate. (genengnews.com)
  • If you're in this phase, you likely learned about your cancer after your doctor had you take a blood test for another reason. (webmd.com)
  • When you're in the chronic phase, your doctor may treat you with a type of anti-cancer drug called a tyrosine kinase inhibitor. (webmd.com)
  • The goal of treatment is to improve your symptoms, get rid of the cancer cells, and make it less likely you will move into the next phase of CML. (webmd.com)
  • In the latest development, these and other technologies are being used to detect imatinib-resistant clones, which are appearing with increasing frequency with longer followup, initially in patients treated in accelerated or advanced stages, more recently in patients treated in the chronic phase. (cap.org)
  • We are seeing it more as time goes on, even in patients treated in the chronic phase of disease. (cap.org)
  • ENESTop evaluated stopping Tasigna treatment in eligible Ph+ CML adults with chronic phase disease after they achieved and sustained deep molecular response (MR) for at least one year with Tasigna but had not achieved and sustained this response previously with Glivec,. (novartis.com)
  • If CML is diagnosed in the accelerated phase and the patient has not yet tried a TKI, one treatment option is to begin TKI therapy. (lls.org)
  • If the CML progressed from chronic phase to accelerated phase during TKI therapy, a patient can try to increase the dosage of the current TKI (if possible) or take another TKI that the patient has not tried before. (lls.org)
  • This system considers the person's age, the percentage of blasts in the blood, the size of the spleen, and the number of platelets. (cancer.org)
  • Tyrosine kinase inhibitor (TKI) therapy is standard treatment for chronic phase CML. (lls.org)
  • If you are already on a tyrosine kinase inhibitor for chronic phase CML, your doctor will have you take a different one. (webmd.com)
  • ENESTnd is a Phase III, randomized, open-label, multicenter study of 846 patients with newly diagnosed Ph+ CML in chronic phase who received TASIGNA 300 mg BID, TASIGNA 400 mg BID, or imatinib 400 mg QD. (tasigna.com)
  • Not all doctors may agree with or follow these cutoff points for the different phases. (cancer.org)
  • For CML, unlike other cancers, doctors use the word "phase" instead of "stage" to describe how advanced the disease has become. (webmd.com)
  • Along with the phase of CML, there are other factors that may help predict the outlook for survival. (cancer.org)
  • The rates of all grade musculoskeletal pain were 42.1% in the first year of the TFR phase versus 14.3% while still taking Tasigna in the consolidation phase. (novartis.com)
  • If you are in the accelerated phase, you may have some of the same symptoms you had in the chronic phase. (webmd.com)
  • Just like with the chronic phase, the goal of treatment is to get rid of or curb your symptoms and try to lower your chances of moving into the next phase. (webmd.com)
  • This phase is manifested by increasing constitutional symptoms, progressive splenomegaly, and increasing refractoriness to standard therapy with progressive leucocytosis and/or thrombocytosis. (bloodjournal.org)